Today, UCB announced top-line interim analysis results from their Phase 3 "BE MOBILE 1" study, that demonstrated the efficacy of bimekizumab, a dual IL-17A and F inhibitor, in adults with active non-radiographic axial spondyloarthritis (nr-axSpA).
Read Article
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. This week we discuss amputations, a $57 billion RA market, an FDA approved drug for Cat arthritis and drug that works in Sjogren's.
Study 126 rheumatic disease (RMD) patients showed that
Our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.
Read Article
Growing awareness of spondyloarthropathies over the last two decades has led to a better understanding of the pathophysiology of spondyloarthritis, and subsequently increased interest in more distinct, disease state specific treatment options.
Read Article
There were several hot topics at ACR21. Here I concentrate on top abstracts in vasculitis.
Read ArticleThe ACR 2021 meeting has concluded. Dr. Jack Cush recounts a few more great abstracts from this past week’s virtual meeting.
Read Article
My favorite three presentations from day 4 (Tuesday) at ACR 2021 included the following.
Read Article
Janet Pope @Janetbirdope( View Tweet )
Olga Petryna @DrPetryna( View Tweet )
Links:
Links:
The third day of ACR 2021 took a big leap in online content. Here is a compilation (with links) of presentations were the “ACRBest” as seen by our RheumNow faculty.
Read Article
TheDaoIndex @KDAO2011( View Tweet )
Growing awareness of spondyloarthropathies over the last two decades has led to a better understanding of the pathophysiology of spondyloarthritis, and subsequently increased interest in more distinct, disease state specific treatment options.
Read Article
National Health Data from France examined biologic use in patients with moderate to severe psoriasis, and found the risk of serious infections (SIE) to be increased with some biologics (infliximab and adalimumab), but not others (etanercept, ustekinumab IL-17 and IL-23 inhibitors or
Read Article